While venture funding is rising, federal policy upheaval may affect women’s health research more acutely than other fields, ...

The president claimed his “most-favored nation” proposal would reduce some pharmaceutical prices by as much as 80%, but the ...

Having now appointed Henry Gosebruch as CEO of the intact company, Galapagos says its priorities are exploring strategic ...

Witty’s departure was unexpected, but follows a downturn in the healthcare company’s financial outlook. He will be replaced ...

The failure is the latest stumble for a cancer drug class that hasn’t lived up to expectations. iTeos will begin a strategic ...

Reports of severe adverse events in some people who received the chikungunya vaccine have spurred regulators in Europe and ...

The proposal would see the HHS set price targets other countries pay for certain medicines, kicking off a round of ...

The biotech has quickly turned a cell therapy approval into one of the more lucrative recent sales for a priority review ...

Improvements in our understanding of the human genome, technological tools like artificial intelligence, and global ...

The big pharma will spend up to $250 million over the next eight years of the collaboration. Elsewhere, CRISPR Therapeutics unveiled new data and Vivo Capital raised funds.

Some providers may need to reduce services, lay off staff or close their doors if Congress enacts major cuts to the ...

Vor Bio, Korro Bio, Insitro and Rallybio revealed plans to lay off chunks of their respective workforces in the latest job ...